Skip to content
Peptigraph home

Retatrutide and BPC-157 Together: What Is Known

Retatrutide and BPC-157 taken together: what each one is, how each is regulated, and what is known about combining them.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
GLP-1 / GIP / glucagon triple agonistInvestigational · phase 3RetatrutideInvestigational triple GIP, GLP-1 and glucagon receptor agonist, not FDA-approved; a phase 3 TRIUMPH trial reported mean weight change of -25.0% at the 12-mg dose versus -3.9% with placebo.[1]GLP-1 & metabolicGastric pentadecapeptidePCAC voted 8–6 for 503A (Jul 2026)BPC-157BPC-157, an experimental gastric pentadecapeptide, not an approved drug; human evidence is a few small uncontrolled reports, including complete symptom resolution in 10 of 12 patients in a bladder pilot.[14]Healing & recovery
Interaction notes

Timing, interactions and safety

Evidence for the combination

No studies tested these together (PubMed search: 2 results, 2 Oct 2026).

Neither is FDA approved for use in people, and we have no sourced data on combining them.
Each component

Side by side

Showing 13 of 14 fields where the two differ. WADA are the same or both unknown.

FieldRetatrutideBPC-157
ClassGLP-1 / GIP / glucagon triple agonistGastric pentadecapeptide
Also calledreta, GLP-3, LY3437943BPC, body protection compound, Pentadecapeptide BPC 157
CategoryGLP-1 & metabolicHealing & recovery
FDA statusInvestigational · phase 3PCAC voted 8–6 for 503A (Jul 2026)
PCAC vote, Jul 2026Not on the Jul 2026 agendaPCAC voted 8–6 for the 503A list (Jul 2026); not finalized
Anti-doping detectionNone reportedanti-doping literature, as of 2 Oct 2026
  • A 2023 method detects BPC-157 and five main metabolites in human urine at very low concentrations.PMID 37959764
  • A 2017 anti-doping lab method detects BPC 157 in urine; the peptide was stable in urine for at least 4 days.PMID 28035768
Half-lifeapproximately 6 dayssubcutaneous · Lancet 2022, PMID 36354040less than 30 minIV and IM (single and repeated) (rat, beagle dog) · Frontiers in pharmacology 2022, PMID 36588717
Evidence strengthHuman RCT evidence, 4 of 4Strongest: The New England journal of medicine 2026, PMID 42814954Human observational evidence, 3 of 4Strongest: Alternative therapies in health and medicine 2025, PMID 40131143
Human studies we summarised11 human (11 randomized or controlled) of 16 summarised3 human (0 randomized or controlled) of 24 summarised
Typical study doses
Vial sizes sold5 mg, 10 mg, 12 mg, 15 mg, 20 mg, 24 mg, 30 mg, 36 mg, 40 mg, 50 mg, 60 mg2 mg, 5 mg, 10 mg, 20 mg
US searches per month823,000 · +172% searches301,000 · Most searched
Named in FDA warning letters, 2026Yes (24 Aug 2026; 31 Mar 2026)Not in the letters we track

What people search

  • reta bpc 15740/mo
  • reta and bpc 15740/mo
  • reta and bpc 157 together20/mo
  • bpc 157 and reta20/mo
  • reta bpc 157 stack10/mo
  • bpc 157 reta10/mo

US monthly searches, Google Keyword Planner, Oct 2026. Shown so you can see which questions this page answers.

Sources

  1. 1Retatrutide phase 3 TRIUMPH-1 results publishedNEJM (PubMed 42814954) · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  2. 2FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
  3. 3Eli Lilly sues six retatrutide sellersEli Lilly (press release) · 2026investor.lilly.comAccessed 2 Oct 2026
  4. 4FDA gives notice that 12 peptides will be removed from Category 2 (nominations withdrawn)FDA · 2026fda.govAccessed 2 Oct 2026
  5. 5Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
  6. 6World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  7. 7LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.Lancet (London, England) · 2022PMID 36354040Accessed 2 Oct 2026
  8. 8Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes.Diabetes, obesity & metabolism · 2026PMID 42608321Accessed 2 Oct 2026
  9. 9Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.The lancet. Diabetes & endocrinology · 2025PMID 40609566Accessed 2 Oct 2026
  10. 10Stable Isotope Labeling-Based Nontargeted Strategy for Characterization of the In Vitro Metabolic Profile of a Novel Doping BPC-157 in Doping Control by UHPLC-HRMS.Molecules (Basel, Switzerland) · 2023PMID 37959764Accessed 2 Oct 2026
  11. 11Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H.Drug testing and analysis · 2017PMID 28035768Accessed 2 Oct 2026
  12. 12Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs.Frontiers in pharmacology · 2022PMID 36588717Accessed 2 Oct 2026
  13. 13Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.Alternative therapies in health and medicine · 2025PMID 40131143Accessed 2 Oct 2026
  14. 14Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study.Alternative therapies in health and medicine · 2024PMID 39325560Accessed 2 Oct 2026
  15. 15Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study.Joint diseases and related surgery · 2026PMID 42542926Accessed 2 Oct 2026
  16. 16PubMed search: ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide BPC"[tiab]) AND (retatrutide[tiab] OR LY3437943[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  17. 17Advisory committee backs 6 of 7 peptides for the 503A listNCPA · 2026ncpa.org

Found an error? Report a correction.